Sanofi Completes Acquisition of Vicebio

Sanofi announced the successful acquisition of Vicebio Ltd, marking a significant step in expanding its vaccine portfolio. This strategic move brings an innovative early-stage combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) to Sanofi's pipeline. The acquisition enhances Sanofi's capabilities in vaccine design, backed by Vicebio's 'Molecular Clamp' technology, and adds a non-mRNA option to its offering.

The integration of Vicebio's vaccine candidate complements Sanofi's existing position in the respiratory vaccines market. It provides broader choices to both physicians and patients, reinforcing Sanofi's commitment to addressing respiratory viruses. This development aligns with the company's broader strategy to leverage opportunities in vaccine development and improve patient outcomes globally.